ArticleIndian journal of pediatrics2026
Impact of Omega-3 Enriched Lipid Emulsions on Retinopathy of Prematurity in Very Low Birth Weight Infants: A Retrospective Cohort Analysis.
Article in Indian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of Omega-3 Enriched Lipid Emulsions on Retinopathy of Prematurity in Very Low Birth Weight Infants: A Retrospective Cohort Analysis - Correspondence.Indian journal of pediatrics · 2026Article
- Impact of Omega-3 Enriched Lipid Emulsions on Retinopathy of Prematurity in Very Low Birth Weight Infants: A Retrospective Cohort Analysis - Authors' Reply.Indian journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo assess the effects of ω-3 long-chain polyunsaturated fatty acid (LCPUFA)-enriched lipid emulsions (SMOFlipid) vs. traditional soybean oil-based lipid emulsions (Intralipid) on the occurrence and severity of retinopathy of prematurity (ROP) in infants with very low birth weight (VLBW).
methodsIn this retrospective cohort study, 301 VLBW infants who received either SMOFlipid or Intralipid for a minimum of 14 d were included. The main outcome measured was the frequency and severity of ROP, with secondary outcomes covering other complications associated with preterm birth.
resultsOf the infants studied, 180 were administered SMOFlipid, while 121 received Intralipid. The incidence of ROP was notably lower in the SMOFlipid group (32.8% vs. 45.5%; RR 0.59; 95% CI 0.36-0.94; P = 0.026). Additionally, the occurrence of severe ROP was reduced by 66.06% in infants given SMOFlipid (5.6% vs. 16.5%; RR 0.30; 95% CI 0.13-0.66; P = 0.002). Multivariate logistic regression suggested that using SMOFlipid was linked to a reduced risk of both ROP (OR 0.44; 95% CI 0.24-0.82; P = 0.010) and severe ROP (OR 0.09; 95% CI 0.03-0.30; P < 0.001). There were no considerable differences noted in other complications associated with preterm birth between the two groups.
conclusionsCompared to Intralipid, SMOFlipid treatment reduced both the risk and severity of ROP. Parenteral supplementation with fish oil-containing emulsions might offer a novel approach to lowering the incidence and severity of ROP in VLBW infants.
Indexed as
Identifiers
39777717What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.